Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome

Table 1

Correlation between CYP39A1 expression in tumor cells and clinicopathologic features of HCC.

Clinicopathological features	All cases	CYP39A1 in HCC tissues (%)		value^a
		Negative	Positive
Gender
Male	123	78 (63.41)	45 (36.59)	0.197
Female	36	27 (75.00)	9 (25.00)
Age at diagnosis (years)
<51	72	51 (70.83)	21 (29.17)	0.245
≥51	87	54 (62.07)	33 (37.93)
Size (diameter, cm)
<5.5	90	57 (63.33)	33 (36.67)	0.411
≥5.5	69	48 (69.57)	21 (30.43)
Differentiation
Well	51	24 (47.06)	27 (52.94)	0.001
Moderately and poorly	108	81 (75)	27 (25)
Nodal metastasis
	135	90 (66.67)	45 (33.33)	0.691
	24	15 (62.50)	9 (37.50)
Distant metastasis
	114	75 (65.79)	39 (34.21)	0.689
	48	30 (62.50)	18 (37.50)
TNM stage
I-II	78	54 (69.23)	24 (30.77)	0.729
III-IV	81	54 (66.67)	27 (33.33)

^aChi-square test.